Research programme: therapeutic antibodies - Dyax/Glenmark
Latest Information Update: 10 Jun 2014
Price : $50 *
At a glance
- Originator Dyax; Glenmark Pharmaceuticals S.A.
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Mar 2007 Early research in an undisclosed indication in the USA (unspecified route)